logo-loader
viewMaxCyte Inc

MaxCyte agrees licensing deal with next-generation CAR T pioneer

The company will receive “undisclosed development, approval and commercial milestones in addition to other licensing fees”

MaxCyte Inc -

Shares in MaxCyte Inc (LON:MXCT) surged 10% after it said it had signed a licensing deal with a company developing the next wave of cancer immunotherapies.

Allogene Therapeutics Inc (NASDAQ:ALLO) will use MaxCyte’s Flow Electroporation platform and ExPERT technology to “develop and advance” its allogeneic CAR T treatments.

MaxCyte will receive “undisclosed development, approval and commercial milestones in addition to other licensing fees”.

"We're honoured to partner with Allogene to help unlock the full potential of its next-generation allogeneic CAR T therapies through utilisation of our Flow Electroporation technology and ExPERT platform," said MaxCyte chief executive Doug Doerfler.

Allogeneic cell therapy being pioneered by Allogene Therapeutics takes the same biological processes that allowed the first generation CAR T treatments to deliver breakthrough clinical benefits, but eliminates the need to create a personalised therapy for each patient.

Instead, AlloCAR T starts with T cells from healthy donors, which is intended to allow for the creation of an inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.

Work using the MaxCyte technology will focus initially on B-lymphocyte antigen CD19 and B-cell maturation antigen targets.

MaxCyte describes its Flow Electroporation system as being able to deliver “virtually any molecule, to any cell, at any scale”. Its ExPERT technology set takes this a step forward by allowing scientists to carry out complex cell engineering.

"MaxCyte's ExPERT platform has become the industry standard in electroporation technology and allows us to increase efficiency and improve yield, which is a critical component to the value proposition of our AlloCAR T therapies," said Alison Moore, chief technical officer of Allogene. 

In early afternoon trading, the stock was changing hands for 135p, up 12.5p.

---adds share price---

Quick facts: MaxCyte Inc

Price: 212 GBX

AIM:MXCT
Market: AIM
Market Cap: £162.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc - Proactive One2One Virtual Event

MaxCyte Inc's (LON:MXCT) Doug Doerfler speaks to investors at the Proactive One2One Virtual Event. They're a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines. For more information visit...

2 days, 12 hours ago

2 min read